LIXTE Biotechnology Reports Transformational 2025 with Clinical Progress and Strategic Expansion

LIXTE Biotechnology Holdings has filed its Annual Report on Form 10-K for the year ended December 31, 2025, detailing a period of substantial progress in its oncology-focused initiatives. The company reported advancing the development of its lead compound LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor, which is part of a pioneering effort in the new field of cancer biology known as activation lethality. Clinical trials for LB-100 have been expanded with additional sites and increased enrollment, with proof-of-concept studies currently in progress for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma.

The strategic expansion included the completion of the acquisition of Liora Technologies Europe Ltd., which enhances LIXTE's cancer treatment platform. Through this subsidiary, the company is developing electronically controlled proton therapy systems, with its proprietary LiGHT System believed to offer significant advantages over existing technologies for tumor treatment. This move diversifies LIXTE's approach to cancer therapy, combining pharmaceutical and med-tech innovations. Financial strengthening was also a key aspect of 2025, as the company raised more than $11 million to bolster its balance sheet, supporting ongoing research and development efforts. Additional information on the company's broader initiatives can be found at https://www.lixte.com.

The implications of these developments are significant for the oncology field, as LB-100's potential to enhance chemotherapies and immunotheries could improve outcomes for cancer patients. Based on published preclinical data, the compound has shown to be well-tolerated at doses associated with anti-cancer activity, marking a step forward in a new treatment paradigm. The comprehensive patent portfolio covering LIXTE's novel approach provides a foundation for future commercialization and clinical applications. The company's forward-looking statements, as detailed in its SEC filings, outline the risks and uncertainties involved, with further disclosures available in its most recent Annual Report on Form 10-K. For full terms of use and disclaimers related to this information, refer to http://IBN.fm/Disclaimer.

Overall, LIXTE's 2025 achievements position it for continued growth and innovation in cancer therapy, with clinical progress and strategic moves aimed at addressing unmet medical needs. The expansion into proton therapy through Liora Technologies adds a technological dimension to its portfolio, potentially broadening its impact on tumor treatment. As the company advances its clinical trials and integrates new acquisitions, the focus remains on developing effective therapies that leverage novel biological targets and treatment modalities. The financial backing secured during the year provides the resources necessary to sustain these efforts, underscoring the importance of this transformational period in LIXTE's trajectory within the competitive oncology landscape.